
Sign up to save your podcasts
Or


The FDA recently announced it will review the safety and efficacy of a number of powerful peptides. In 2023, based on safety concerns and reports that providers were treating patients irresponsibly, the FDA assigned a number of peptides for Category 2, effectively banning US pharmacies from compounding them. Today, Dr. Seeds addresses the why, the how, and the what’s next.
Learn more about the SSRP Institute
Follow for more!
Instagram: @williamseedsmd | @redoxmedicalgroup
Youtube: Subscribe Here
By William Seeds, MD4.8
1313 ratings
The FDA recently announced it will review the safety and efficacy of a number of powerful peptides. In 2023, based on safety concerns and reports that providers were treating patients irresponsibly, the FDA assigned a number of peptides for Category 2, effectively banning US pharmacies from compounding them. Today, Dr. Seeds addresses the why, the how, and the what’s next.
Learn more about the SSRP Institute
Follow for more!
Instagram: @williamseedsmd | @redoxmedicalgroup
Youtube: Subscribe Here

7,202 Listeners

4,991 Listeners

12,140 Listeners

268 Listeners

4,903 Listeners

3,459 Listeners

9,244 Listeners

159 Listeners

132 Listeners

298 Listeners

1,683 Listeners

1,208 Listeners

120 Listeners

3,093 Listeners

81 Listeners